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Abstract: Brucellosis is one of the infectious diseases that may increase 
osteoporosis risk. Bone formation and destruction markers were analyzed in the 
examination of osteoporosis risk. There have been many studies on the effect of a 
variety of diseases on the bone, but no studies have conducted for brucellosis. This 
study is one of the rare studies showing the effect of brucellosis on a bone. The 
purpose of this study is that whether age, agglutination level, having brucellosis at 
the time or before, and gender knowledge of patients have effects on osteoporosis 
by using bone formation and destruction markers. Between 01/04/2015 and 
31/12/2017, blood samples were taken from 40 patients with brucellosis and seven 
patients whose treatment completed at least six months before. Then biochemical 
markers were studied on these blood samples. ELISA washer and reader (Biotek, 
Novatek, Istanbul, Turkey) was used to obtain the values of bone formation and 
destruction markers. There was a significant difference, according to H. Osteocalcin 
(Human Osteocalcin/Bone Gla Protein), in terms of bone formation markers and was 
higher in women. Having brucellosis at the time was significant according to Human 
deoxypyridinoline (DPD) and Human C-telopeptide of type I collagen (CTX-I) in 
terms of bone destruction markers and was higher in brucellosis. The bone formation 
and destruction markers strongly correlated with each other in the same direction. It 
is thought that brucellosis can increase bone destruction markers, especially DPD 
(Human deoxypyridinoline) and CTX-I; therefore, osteoporosis risk in brucella 
patients can reduce by implementing a treatment plan that closely monitors bone 
destruction markers. 
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INTRODUCTION 
 The bone is in the cycle of formation and destruction throughout the lifetime. 
The level of bone formation and destruction in normal conditions balances each 
other tightly (Markus, 2005). According to literature, an imbalance between bone 
formation and destruction can lead to bone diseases, including osteoporosis 
(Rinaldo et al., 2015). Osteoporosis is a systemic skeletal disease characterized by a 
decrease in bone mass and microstructural degradation, which may increase bone 
fragility and fracture danger and consequently cause serious complications (Van Den 
Bergh, Van Geel & Geusens, 2012). The risk of osteoporosis increases due to age 
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or some diseases or drug usage (Office of the Surgeon General, 2004). Brucellosis 
is an infectious disease (Alizadeh et al., 2018) and seen in our region, namely in the 
Mediterranean region (Bilgehan, 2000; Gotuzzo & Cellillo, 1992). It mostly affects the 
musculoskeletal system. As far as we know, a few studies have done about the 
relationship between Brucella and osteoporosis. In one study, it was reported that 
Brucella could sometimes cause destructive septic arthritis in the joint, and 
osteoporotic appearance can be seen in the radiological image of this destructive 
arthritis in the advanced period (Günal et al., 2011). To estimate the relative risks of 
hip fracture in postmenopausal women, CTX-I has used, and it shows promise in 
predicting like these problems of osteoporosis (Swaminathan, 2001). DPD is 
particular for bone, in that it is found in relatively significant amounts only in bone 
and has been shown to correlate well with bone turnover (Robins, 1995). Col-I is the 
main constituent of the bone matrix. It is a significant marker of bone destruction 
(Eriksen et al., 1993).    
 We evaluated that brucellosis may affect the bone formation or bone 
resorption due to its relationship with the musculoskeletal system, so we analyzed 
whether brucellosis is risky in terms of osteoporosis. To evaluate the risk, we 
measured the effects of brucellosis on bone formation and destruction markers 
through our patients.  
 
MATERIALS AND METHODS 
 Patients in this study were examined in the infection clinic with the suspicion 
of brucellosis between 01/04/2015 and 31/12/2017. The ethics committee report of 
this study approved by the presidency of Biomedical Research Ethics Committee, 
Medical Faculty, Adıyaman University, with approval code 2015/02-1 on 25/03/2015. 
Patients with clinical symptoms and with brucella coombs agglutination and wright 
agglutination test 1/160 and above, diagnosed with Brucella, were included in the 
study. The number of these patients was 40. The other seven patients included in 
the study came to the clinic for checking. They had completed the Brucella treatment 
at least six months ago and had no clinical findings since then. The effects of 
gender, agglutination level, and age knowledge of 47 patients in terms of bone 
formation markers, destruction markers, and bone formation/bone destruction values 
to measure the risk of osteoporosis.  Biochemical markers were studied in these 47 
blood samples taken from patients during diagnosis or follow-up.  
 Those biochemically used from these tests are H. Osteocalcin (Human 
Osteocalcin/Bone Gla Protein), Human Procollagen I N-terminal peptide (PINP), 
Human bone alkaline phosphate (BALP), Human C-telopeptide of type I collagen 
(CTX-I), Human deoxypyridinoline (DPD) and Human collagen type I (Col-I). The first 
three markers are about the bone formation, and the last three markers are about 
bone destruction. Biochemical markers were obtained by the following methods. 
Patient Serums  
 Twenty-one males and Twenty-six females, with a total of Forty-seven 
patients, were included in this study. Blood from these patients centrifuged for 10 
minutes at 5000 rotations per minute (rpm), and the separated serums stored at -
20°C. Patient serums were warmed at room temperature before the study and were 
centrifuged again at 2000-3000 rpm for 10 to 20 minutes. The centrifugation 
repeated when sediments were formed during storage after the supernatants were 
carefully collected. Samples were stored at -80°C for approximately three months to 
prevent biological activity and contamination loss. Hemolytic samples not included in 
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the study since hemolysis in the samples would affect the test result. Samples 
brought to room temperature before testing. 
Kits   
 The kits used in this study were H. Osteocalcin, PINP, CTX-I, DPD, BALP, 
and Col-I (ELISA Kit, Shanghai YL Biotech Co, Ltd. YL biont, Jiading District, 
Shanghai). Each kit contained similar materials as content (Coated ELISA plate, 
Standard dilution, Chromogen solution A, and B and Streptavidin-HRP). TMB 
Substrate Wash Buffer and Stop Solution were stored at 4°C and others at -20°C 
before opening. Kits were brought to room temperature and started to use. Some 
necessary materials prepared for the use of kits: Incubator that can provide stable 
incubation conditions up to 37°C ± 0.5°C, microplate reader with 450 ± 10nm filter, 
precision pipettes and disposable pipette tips, distilled water, absorbent paper, and 
gloves. Dilution of the standard solutions was started by adding 120μl of standard 
diluent to the original standard of 120μl in dilution ratio of 1280nmol / L and by 
obtaining standard 5. Then, for serial dilutions; Standard 4 (320nmol / L) obtained by 
adding 120μl standard diluent to 120μl Standard 5, Standard 3 (160nmol / L) 
obtained by adding 120μl standard diluent to 120μl Standard 4, Standard 2 (80nmol / 
L) obtained by adding 120μl standard diluent to 120μl Standard 3, and Standard 1 
(40nmol / L) was obtained by adding 120μl standard diluent to 120μl Standard 2. 
Quantitative measurement of in vitro H. Osteocalcin, PINP, Col-I, CTX-I, DPD, 
BALP, and Col-I levels in serum, plasma, homogenized tissue, or other body fluids 
provided by sandwich enzyme immunoassay method. 
Working Principles 
 The number of samples determined the number of strips needed to tested 
according to the standards. Three or more wells arranged, each containing a 
standard solution, empty well, and patient serum to tested. According to this, 
Chromogen solutions A and B and stop solution added to the empty well. 50μl 
standard and streptavidin-HRP 50μl added to standard solution well. In the patient 
sample, well to be tested, 40μl of patient serum, and then 10μl of antibodies in the 
corresponding kit and 50μl of streptavidin-HRP were added. Then closed with plate 
membrane. The plates were then incubated at 37°C for 60 minutes with gentle 
shaking. 
ELISA Washer and Reader 
 After incubation, washing concentration (30X) diluted with distilled water for 
later use. Carefully remove the plate membrane, empty the liquid, and rinse the 
remaining liquid. Each well filled with a washing solution. After waiting 30 seconds, 
the liquid was drained and then repeated five times by using an ELISA plate washer 
(Biotek, Novatek, İstanbul, Turkey). Then 50μl of chromogen A and 50μl of 
chromogen B solution were added to each well and shaken gently. Incubated for 10 
minutes at 37℃, away from light for color development. After that, a 50 µl stop 
solution placed in all wells, and ELISA plate reader (Biotek, Novatek, İstanbul, 
Turkey) used for measuring at 450 nm wavelength within 10 minutes. Then, the wells 
drained entirely, and the absorbance (OD) of each well that had to perform within 10 
minutes after the stop solution added measured under a wavelength of 450nm. 
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Computation of Results 
 The concentration of the patient sample corresponding to the OD values 
calculated after calculating the linear regression equation of the standard curve 
according to the concentrations of the standards and the respective OD values.  
Statistical Analysis 
 All data evaluated by Independent Sample t-Test and correlation analysis. 
The alpha value lower than <0.05 was considered significant for Independent 
Sample t-Test, and this shows that it is in the 95 percent confidence interval. In 
addition to available variables related to bone formation and destruction markers, we 
defined new variables using the idea of bone formation/bone destruction, which is by 
dividing two bone formation markers into three bone destruction markers. By doing 
so, we obtained (H. Osteocalcin)/(DPD), (H. Osteocalcin)/(CTX-I), (H. 
Osteocalcin)/(Col-I), (BALP)/(DPD), (BALP)/(CTX-I) and (BALP)/(Col-I) values. 
 
RESULTS AND DISCUSSION 
Gender 
 The proportion of genders in this study is quite close to each other. An 
independent sample t-test was applied to denote, in which bone markers differ 
concerning gender attributes and the results shown in Table 1. According to results, 
H. Osteocalcin differed between males and females at the level of significance 
(0.034 < 0.05) and was higher in women. On the other hand, there could be another 
bone marker candidate called BALP if the sample size could increase since its 
significance value (0.076) is very close to 0.05.  
 
Table 1. The Results of Gender in Terms of Bone Formation Markers. 
 
Levene's Test for Equality of Variances 
 F Sig
. 
t df Sig. (2 
tailed) 
 
Human 
Procollagen I N-
terminal peptide 
Equal variances 
assumed 
,397 ,53
2 
,727 45 ,471 
Equal variances 
not assumed 
  ,727 42,975 ,471 
 
Human bone 
alkaline 
phosphate 
Equal variances 
assumed 
1,064 ,308 1,816 45 ,076 
Equal variances 
not assumed 
  1,851 44,925 ,071 
 
H. 
Osteocalcin 
Equal variances 
assumed 
7,878 ,007 2,095 45 ,042 
Equal variances 
not assumed 
  2,195 42,777 ,034 
 
 An independent sample t-test also performed to denote which bone 
destruction markers differ concerning gender and the results shown in Table 2. 
According to the results, none of the bone destruction markers is statistically 
significant concerning gender attributes. On the other hand, if the sample size 
increased, there would be a potential candidate, which is CTX-I, since its 
significance value (0.073) is very close to 0.05. Besides, there was no statistical 
significance between bone formation/bone destruction values and gender.  
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Table 2. The Results of Gender in Terms of Bone Destruction Markers. 
 
 
Having Brucellosis at the Time or Before  
 The number of patients we evaluated in this study was 47. At the time of the 
study, the number of patients with brucellosis was 40, while the number of patients 
who had brucellosis before was 7. An independent two-sample t-test performed to 
denote which bone markers differ when patients are at a stage of having brucellosis 
or having it before; the obtained results shown in Table 3.  
 
Table 3. The Results of Having Acute Brucellosis at The Time or Before in Terms  
of Bone Formation Markers. 
 
Levene's Test for Equality of Variances 
 F Sig. t df Sig (2-tailed) 
Human 
Procollagen I 
N-terminal 
peptide 
Equal variances 
assumed 
2,033 ,161 -1,249 45 ,218 
Equal variances 
not assumed 
  
-1,668 11,530 ,122 
Human bone 
alkaline 
phosphate 
Equal variances 
assumed 
1,867 ,179 -,815 45 ,420 
Equal variances 
not assumed 
  
-1,201 13,837 ,250 
 
H. 
Osteocalcin 
Equal variances 
assumed 
4,855 ,033 -1,137 45 ,262 
Equal variances 
not assumed 
  
-2,030 23,064 ,054 
 
 Even though none of them is statistically significant, one of them, H. 
Osteocalcin, with 0.054 significance level, would be potentially found significant if the 
sample size increased.    
 Table 4 denotes which bone destruction markers differ when patients are at a 
stage of having brucellosis or having it before. We here run an independent two-
sample t-test. Two of them, DPD and CTX-I, are found statistically significant since 
Levene's Test for Equality of Variances 
  F Sig. t df Sig. (2-
tailed) 
Human  
Deoxypyridino
line 
Equal variances 
assumed 
1,122 ,295 1,631 45 ,110 
Equal variances 
not assumed 
  
1,667 44,99
0 
,102 
Human C-
telopeptide of 
type I 
collagen 
Equal variances 
assumed 
3,677 ,062 1,834 45 ,073 
Equal variances 
not assumed 
  
1,887 44,89
7 
,066 
Human 
Collagen  
Type I 
Equal variances 
assumed 
1,250 ,269 1,684 45 ,099 
Equal variances 
not assumed 
  
1,699 44,17
2 
,096 
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their significance levels are (0.024<0.05) and (0.106<0.05), respectively. If the 
sample size increased, then the third one, Col-I, would also be found statistically 
significant since its significance level (0.054) is very close to 0.05.  
 
Table 4. The Results of Having Acute Brucellosis at The Time or Before in Terms  
of Bone Destruction Markers. 
 
Levene's Test for Equality of Variances 
 F Sig. T df Sig. (2-
tailed) 
 
Human 
deoxypyridinoline 
Equal variances 
assumed 
3,824 ,057 -1,394 45 ,170 
Equal variances 
not assumed 
  
-2,434 21,471 ,024 
Human C-
telopeptide of 
type I collagen 
Equal variances 
assumed 
5,137 ,028 -1,797 45 ,079 
Equal variances 
not assumed 
  
-2,711 14,521 ,016 
 
Human Collagen  
Type I 
Equal variances 
assumed 
1,876 ,178 -1,674 45 ,101 
Equal variances 
not assumed 
  
-2,178 11,063 ,052 
 
We examined the results between having brucellosis at the time or before with bone 
formation/bone destruction values. There was no statistical significance between 
having brucellosis at the time or having it before concerning the bone formation/bone 
destruction values.  
Age and Agglutination Level 
 Table 5 shows the correlation between the attributes (bone markers). The first 
one is PINP and BALP with 0.86, which means that there is a strong linear 
relationship between those. The second one is PINP and H. Osteocalcin with 0.81, 
which means that there is a strong linear relation between them. The third one is 
BALP and H. Osteocalcin, with 0.88, which means that there is a strong linear 
relation between them. We here run correlation analysis among the attributes 
presented in Table 5. Also, Age is not a statistically significant variable with bone 
markers. The same is true for the Agglutination level.   
 Table 6 shows the correlation among the attributes (bone destruction 
markers). The first one is DPD and CTX-I with 0.939, which means that there is a 
solid linear relation between those. The second one is DPD and Col-I with 0.922, 
which means that there is a solid linear relation between them. The third one is CTX-
I and Col-I with 0.904, which means that there is a solid linear relation between 
them. We here run correlation analysis among the attributes presented in Table 6. 
Also, Age is not a statistically significant variable with bone destruction markers. The 
same is true for the Agglutination level. 
The correlations among bone formation/bone destruction markers with age and 
agglutination were analyzed. Age and agglutination levels are not found statistically 
significant with them. However, there exist both high and low correlations among 
them. Here we sample the highest and the lowest significant correlations. While the 
highest correlation between (BALD)/(DPD) and (H. Osteocalcin)/(DPD) is 0.99, the 
lowest correlation between (H. Osteocalcin)/(CTX-I) and (BALP)/(COL-I) is 0.36. 
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According to results, the cycle of bone formation and bone destruction continue as 
routine in brucellosis patients. DPD and CTX-I levels are found significant in 
brucellosis patients.  
 
Table 5. The Results of Correlation Analysis of Age, Agglutination Level Concerning 
Bone Formation Markers. 
 
Correlations 
 
Age 
Agglutina
tion Level 
Human 
Procolla 
gen I N-
terminal 
peptide 
Human 
bone 
alkaline 
phosph
ate 
H. 
Osteoca
lcin 
 
 
Age 
Pearson 
Correlation 
1 -,028 ,240 ,223 ,284 
Sig. (2-tailed)  ,850 ,104 ,131 ,053 
N 47 47 47 47 47 
 
Agglutinati
on 
Level 
Pearson 
Correlation 
-,028 1 -,012 ,090 ,137 
Sig. (2-tailed) ,850  ,939 ,549 ,360 
N 47 47 47 47 47 
Human 
Procolla- 
gen I N-
terminal 
peptide 
Pearson 
Correlation 
,240 -,012 1 ,861** ,810** 
Sig. (2-tailed) ,104 ,939  ,000 ,000 
N 47 47 47 47 47 
Human 
bone 
alkaline 
phosphate 
Pearson 
Correlation 
,223 ,090 ,861** 1 ,882** 
Sig. (2-tailed) ,131 ,549 ,000  ,000 
N 47 47 47 47 47 
 
H. 
Osteocalc
in 
Pearson 
Correlation 
,284 ,137 ,810** ,882** 1 
Sig. (2-tailed) ,053 ,360 ,000 ,000  
N 47 47 47 47 47 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 Bone formation and destruction are like a cycle; it continues throughout life. 
When the accumulative influence of bone destruction and deterioration of bone 
structure happen, then osteoporosis can be developed (Rinaldo et al., 2015). 
Osteoporosis can cause fractures, so people who have osteoporosis are at high risk. 
Primary osteoporosis is known as the most common form of osteoporosis, and 
primary osteoporosis is seen in the old ages because they suffer from excessive 
bone destruction. The reason why excessive bone destruction frequently happens is 
the disruption of the cycle of bone formation and destruction (4). Brucellosis is also 
an infectious disease, and in this study, we aimed to evaluate the relationship 
between brucellosis and risk of osteoporosis through the bone markers. It is seen 
that bone formation and destruction markers were correlated. Previous studies have 
been conducted to analyze the relationship between osteoporosis and different 
diseases through bone markers. In a study, Biochemical markers linked with bone 
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remodeling, including N-serum terminal propeptide of type 1 procollagen (sPINP) 
and serum Cross-linked C telopeptides of type I collagen (sCTX1) are significantly 
associated with the risk of future osteoporotic vertebral fractures. It was found that 
the combined use of bone markers and a history of previous fractures determined 
osteoporotic fracture risk in postmenopausal women (Ivaska et al., 2010). 
 
Table 6. The Results of Correlation Analysis of Age, Agglutination Level Concerning 
Bone Destruction Markers.  
 
Correlations 
  
 
Age 
 
Human 
deoxypyridin
oline 
Human C-
telopeptide 
of type I 
collagen 
 
Human 
Collagen 
Type I 
 
Aggluti
nation 
level 
 
Age 
Pearson 
Correlation 
1 ,269 ,147 ,225 -,028 
Sig. (2-tailed)  ,068 ,325 ,129 ,850 
N 47 47 47 47 47 
Human 
deoxypyri-
dinoline 
Pearson 
Correlation 
,269 1 ,939** ,922** ,045 
Sig. (2-tailed) ,068  ,000 ,000 ,763 
N 47 47 47 47 47 
Human C-
telopeptide 
of type I 
collagen 
Pearson 
Correlation 
,147 ,939** 1 ,904** ,074 
Sig. (2-tailed) ,325 ,000  ,000 ,619 
N 47 47 47 47 47 
Human 
Collagen 
Type I 
Pearson 
Correlation 
,225 ,922** ,904** 1 ,016 
Sig. (2-tailed) ,129 ,000 ,000  ,916 
N 47 47 47 47 47 
 
Agglutina-
tion level 
Pearson 
Correlation 
-
,028 
,045 ,074 ,016 1 
Sig. (2-tailed) ,850 ,763 ,619 ,916  
N 47 47 47 47 47 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 In another study, the association between osteoporosis, obesity, and type 2 
diabetes measured by researchers. Lower fasting bone turnover markers, 
Osteocalcin, and collagen type 1 cross-linked C-terminal telopeptide found to 
suppressed in insulin resistance independent of adiposity (Tonks et al., 2017). In this 
study, we found that gender was of significance in terms of H. Osteocalcin, and this 
significance was higher in women. Besides, if the number of data increased, then 
there may be a high chance that having brucellosis at the time or before might be 
significant in terms of H. Osteocalcin. When we analyzed having brucellosis at the 
time or before in terms of bone destruction markers, it was found that CTX-I is 
statistically significant.  In this study, we have evaluated that if the data set 
increased, gender has the potential to be significant in terms of BALP, and also, 
there is no significance for gender in terms of bone destruction markers. When we 
analyzed having brucellosis at the time or before in terms of bone formation and 
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bone destruction markers, we found that statistically having brucellosis at the time or 
before had no significance in the case of bone formation markers. In another study, 
while those who have diabetes had lower C-terminal of type 1 collagen (CTx) levels 
than those who did not overall, those with diabetes and high CTx levels had a 3.5-
fold increase in total fracture rates. Nevertheless, the rise in vertebral fracture did not 
reach statistical significance compared to nondiabetic individuals with high CTx 
(Alexander et al., 2018). In another study, by dividing different values of PINP to 
different values of beta C-terminal cross-linked telopeptide of type I collagen (bCTX), 
a classification model for bone turnover status as six subtypes were recommended 
by researchers. Afterward, in orthogeriatric patients, altered subtypes were shown to 
be closely related to the presence of nonvertebral fractures, comorbidities, and 
poorer in-hospital outcomes (Jiajue et al., 2014).       
 In this study, we evaluated gender, having brucellosis at the time or before, 
agglutination level, age in terms of the values that we obtained by dividing bone 
formation markers/bone destruction markers, and found that there was no 
significance. The weak point of this study was that bone densitometry could not be 
performed in patients, and radiological imaging methods could not be performed 
because of the absence of ileitis and spondylodiscitis findings, so skeletal 
involvement could not be evaluated in patients.  
 
CONCLUSION 
 In conclusion, the bone formation and bone destruction cycle of brucellosis 
patients continue as a routine. In patients with brucellosis, DPD, and CTX-I, which 
are bone destruction markers, increased. It is thought that it may be a risk factor for 
osteoporosis in later stages. In these patients, treatment planning options may be 
given in order to prevent the development of osteoporosis in the early period by 
following the bone destruction markers, but more studies are needed. 
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